Efficacy and safety of long-term treatment with dupilumab for moderate to severe atopic dermatitis

被引：0
|
作者：
Ikeda, M. [1 ,2 ]
Uehara, H. [1 ,2 ]
Tsuge, M. [1 ,2 ]
机构：
[1] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat Acute Med, Okayama, Japan
[2] Fukuyama City Hosp, Dept Pediat, Fukuyama, Hiroshima, Japan
来源：
ALLERGY | 2019年 / 74卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
PD0311
引用
收藏
页码：182 / 182
页数：1
相关论文
共 50 条
  • [1] A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
    Dong Hyek Jang
    Seok Jae Heo
    Hyung Don Kook
    Dong Heon Lee
    Hye Jung Jung
    Mi Yeon Park
    Jiyoung Ahn
    [J]. Scientific Reports, 11
  • [2] A 52 weeks dupilumab treatment for moderate to severe atopic dermatitis in Korea: long-term efficacy and safety in real world
    Jang, Dong Hyek
    Heo, Seok Jae
    Kook, Hyung Don
    Lee, Dong Heon
    Jung, Hye Jung
    Park, Mi Yeon
    Ahn, Jiyoung
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [3] Long-Term Safety and Efficacy of Open-Label Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
    Deleuran, Mette
    Thaci, Diamant
    Beck, Lisa A.
    Forman, Seth
    Soong, Weily
    Hussain, Iftikhar
    Bissonnette, Robert
    Bouaziz, Jean-David
    Gelfand, Joel
    Sher, Lawrence
    Chen, Zhen
    Akinlade, Bolanle
    Gadkari, Abhijit
    Eckert, Laurent
    Graham, Neil M. H.
    Pirozzi, Gianluca
    Ardeleanu, Marius
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 139 (02) : AB381 - AB381
  • [4] Long-term safety and efficacy of open-label dupilumab in patients with moderate-to-severe atopic dermatitis
    Deleuran, M.
    Thaci, D.
    Beck, L.
    Forman, S.
    Soong, W.
    Hussain, I.
    Bissonnette, R.
    Bouaziz, J.
    Gelfand, J.
    Lawrence, S.
    Chen, Z.
    Akinlade, B.
    Gadkari, A.
    Eckert, L.
    Graham, N.
    Ardeleanu, M.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 34 - 34
  • [5] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Zheng, Y.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 : 72 - 72
  • [6] Clinical efficacy and safety of Dupilumab for the treatment of moderate to severe atopic dermatitis in Korea
    Kim, Jongwook
    Kim, Yeona
    Won, Sang-Hyeon
    Bae, Kyung-Nam
    Lee, Jungsoo
    Shin, Kihyuk
    Kim, Hoonsoo
    Ko, Hyunchang
    Kim, Moon-Bum
    Kim, Byungsoo
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB136 - AB136
  • [7] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    [J]. ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [8] A 52 WEEKS RETROSPECTIVE STUDY OF DUPILUMAB TREATMENT FOR MODERATE TO SEVERE ATOPIC DERMATITIS IN KOREA: LONG-TERM EFFICACY AND SAFETY OF DUPILUMAB IN REAL WORLD PRACTICE
    Ahn, Jiyoung
    Jang, Dong Hyek
    Heo, Seok Jae
    Lee, Dong Heon
    Jung, Hye Jung
    Park, Mi Yeon
    Seo, Seoung Jun
    [J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 13 - 13
  • [9] PATIENT PERCEPTION OF TREATMENT WITH LONG-TERM DUPILUMAB MONOTHERAPY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Simpson, E.
    Lacour, J.
    Beck, L.
    Zhang, H.
    Aamodt, K.
    Rossi, A.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2021, 127 (05) : S55 - S56
  • [10] LONG-TERM SAFETY IN ADULTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS TREATED WITH DUPILUMAB UP TO 4 YEARS
    Blauvelt, A.
    Eichenfield, L.
    Sierka, D.
    Chen, Z.
    Khokhar, F.
    Marco, A. Rodriguez
    Shabbir, A.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2022, 129 : S19 - S19
12345